Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 6.9%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s share price traded down 6.9% on Monday . The stock traded as low as $12.79 and last traded at $12.79. 53,092 shares changed hands during trading, a decline of 85% from the average session volume of 351,125 shares. The stock had previously closed at $13.74.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Morgan Stanley decreased their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Canaccord Genuity Group reiterated a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Finally, BMO Capital Markets decreased their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Y-mAbs Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $21.14.

Y-mAbs Therapeutics Stock Down 5.2 %

The stock has a 50 day simple moving average of $12.76 and a 200 day simple moving average of $13.49. The company has a market capitalization of $595.49 million, a price-to-earnings ratio of -28.33 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative net margin of 28.44% and a negative return on equity of 24.88%. The business had revenue of $22.80 million for the quarter, compared to the consensus estimate of $23.09 million. During the same period last year, the firm posted ($0.14) EPS. As a group, analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current year.

Insider Buying and Selling

In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now owns 67,681 shares in the company, valued at $877,822.57. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at approximately $449,514. The disclosure for this sale can be found here. Insiders have sold a total of 100,000 shares of company stock valued at $1,338,100 over the last quarter. Corporate insiders own 21.50% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC acquired a new position in Y-mAbs Therapeutics in the fourth quarter worth approximately $562,000. Ameritas Investment Partners Inc. grew its position in Y-mAbs Therapeutics by 39.9% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock worth $60,000 after purchasing an additional 1,056 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares in the last quarter. Boston Partners purchased a new position in Y-mAbs Therapeutics during the 1st quarter worth approximately $556,000. Finally, Rice Hall James & Associates LLC grew its position in Y-mAbs Therapeutics by 4.2% during the 2nd quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after purchasing an additional 3,589 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.